Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08DPN
|
|||
| Former ID |
DIB009298
|
|||
| Drug Name |
GSK-625433
|
|||
| Synonyms |
NS5B HCV polymerase inhibitors, GlaxoSmithKline; SB-711845; SB-750330; 625433
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H32N4O5S
|
|||
| Canonical SMILES |
CC(C)(C)C1=C(C=C(C=C1)C(=O)N2C(C(CC2(CN3C=CC=N3)C(=O)O)COC)C4=NC=CS4)OC
|
|||
| InChI |
1S/C26H32N4O5S/c1-25(2,3)19-8-7-17(13-20(19)35-5)23(31)30-21(22-27-10-12-36-22)18(15-34-4)14-26(30,24(32)33)16-29-11-6-9-28-29/h6-13,18,21H,14-16H2,1-5H3,(H,32,33)/t18-,21-,26-/m1/s1
|
|||
| InChIKey |
HLQXYDHLDZTWDW-KAWPREARSA-N
|
|||
| CAS Number |
CAS 885264-71-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00439959) Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults. U.S. National Institutes of Health. | |||
| REF 2 | Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase . Antimicrob Agents Chemother. 2009 June; 53(6): 2544-2552. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.